Sightsavers Logo
Research centre
  • Home
  • About us
  • Research approach
  • Research studies and publications
  • Evidence gap maps
Join in:
  • Join in: Facebook
  • Join in: Twitter
  • Join in: Instagram
  • Join in: LinkedIn
  • Join in: YouTube
  • Global
  • Close search bar
    Donate
    • Home
    • About us
    • Research approach
    • Research studies and publications
    • Evidence gap maps

    Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma

    Methodological quality of the review: Low confidence

    Author: Holmstrom S, Buchholz P, Walt J, Wickstrøm, Aagren M

    Geographical coverage: Not specified

    Sector: Glaucoma

    Sub-sector: Treatment of primary open angle glaucoma

    Equity focus: Adults more than 18 years old

    Review type: Effectiveness review

    Quantitative synthesis method: Narrative/thematic synthesis

    Qualitative synthesis method: Not applicable

    Background: The most commonly used treatments for glaucoma patients are prostaglandin analogues for controlling intra-ocular pressure (IOP). Therefore, it is important to assess the efficacy of these drugs.

    Objectives: To evaluate different measures of efficacy of the IOP-lowering lipid class agents (bimatoprost, latanoprost and travoprost) in the treatment of primary open angle glaucoma (POAG).

    Main findings: In total, authors included 42 studies in this review, in which 9295 patients participated in the included trials. The analysis showed that timolol, on average, had a weighted mean IOP reduction of 22.2%, while latanoprost, travoprost and bimatoprost had a weighted mean IOP reduction of 26.7%, 28.7% and 30.3% respectively.

    Analysis of target achievement to various IOP levels showed that bimatoprost was more effective than latanoprost. The direct comparisons also showed that bimatoprost is the most efficacious treatment, however authors stated that it is not conclusive whether latanoprost or travoprost is better in reducing IOP. The authors concluded that head-to-head studies confirm that bimatoprost is likely to be the most efficacious treatment in lowering IOP.

    Authors noted that lipid class drugs are superior to timolol in IOP reduction and reducing IOP to a target level. Therefore, it was suggested they are the first-line therapy alongside beta-blockers. In addition, authors emphasised the importance of taking into account the time of IOP measurement when combining and evaluating the data.

    Methodology: MEDLINE and EMBASE were searched for English-language literature from January 1992 to October 2004. The following search terms were used: glaucoma, ophthalmic, clinical trial and either travoprost, latanoprost or bimatoprost. Also, references from relevant articles were searched for additional studies.

    The following criteria were considered for selection of articles: English language from 1992 to October 2004, randomised controlled trials (RCTs) double masked or investigator masked, adults more than 18 years old, diagnosis including primary open angle glaucoma. Two reviewers assessed the articles independently of each other and had to agree on inclusion. Also, two reviewers extracted data and made the estimations independently before agreeing on results.

    Results were combined based on the mean estimates of efficacy of the included studies weighted by number of patients.

    Applicability/external validity: No methods were used either to assess the applicability/external validity of the results or to discuss how generalizable the results are.

    Geographic focus: This review focuses on all countries, however it is not clear if the authors found any results from low/middle-income settings or not.

    Summary of quality assessment: Authors conducted a narrative synthesis of the findings. Authors appropriately reported inclusion/exclusion criteria used for study selection. However, this review had some important limitations. The authors did not avoid publication and language bias in the search as only articles written in English were included in the review. Authors used appropriate methods to screen studies for inclusion and extract data of included studies.

    However, authors did not appraise the methodological quality of studies, and as such it is not clear if studies are subject to high or low risk of bias. This also has an impact on the overall reliability of findings of this review. Therefore, there is low confidence in the conclusions about the effects of this study.

    Publication source: Holmstrom S, Buchholz P, Walt J, Wickstrøm , Aagren M. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin. 2005 Nov;21(11):1875-83. Source
    Sightsavers Logo
    Research centre
    • Join in:
    • Join in: Facebook
    • Join in: X
    • Join in: Instagram
    • Join in: LinkedIn
    • Join in: YouTube

    Protecting sight, fighting disease and promoting equality for all

  • Accessibility
  • Sightsavers homepage
  • Our policies
  • Media centre
  • Contact us
  • Jobs
  • Cookies and privacy Terms and conditions Modern slavery statement Safeguarding

    © 2025 by Sightsavers, Inc., Business Address for all correspondence: One Boston Place, Suite 2600, Boston, MA 02108.

    Our website uses cookies

    To make sure you have a great experience on our site, we’d like your consent to use cookies. These will collect anonymous statistics to personalise your experience.

    Manage preferences

    You have the option to enable non-essential cookies, which will help us enhance your experience and improve our website.

    Essential cookiesAlways on

    These enable our site to work correctly, for example by storing page settings. You can disable these by changing your browser settings, but some parts of our website will not work as expected.

    Analytics cookies

    To improve our website, we’d like to collect anonymous data about how you use the site, such as which pages you read, the device you’re using, and whether your visit includes a donation. This is completely anonymous, and is never used to profile individual visitors.

    Advertising cookies

    To raise awareness about our work, we’d like to show you Sightsavers adverts as you browse the web. By accepting these cookies, our advertising partners may use anonymous information to show you our adverts on other websites you visit. If you do not enable advertising cookies, you will still see adverts on other websites, but they may be less relevant to you. For info, see the Google Ads privacy policy.